|Bid||515.00 x 0|
|Ask||516.00 x 0|
|Day's range||510.65 - 519.00|
|52-week range||5.02 - 541.00|
|Beta (5Y monthly)||0.33|
|PE ratio (TTM)||30.17|
|Earnings date||30 Mar 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||03 Oct 2019|
|1y target est||712.50|
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
It has been a wild ride since this column first assessed CVS four years ago but the veterinary services group has come good, as its shares have galloped to a fresh record high. However, a pleasing capital gain of almost 70pc means the shares now trade on more than 50 times consensus earnings forecasts for the current year. Even allowing for the strength of the business model, the health of the balance sheet and the long-term prospects of the pet care market, such a rating feels lofty and as a result it may be time to book a gain and move on, albeit reluctantly. CVS’s interim results last month showed that the firm was back on track after the combination of acquisitions, staff shortages and debt got it into a tangle a couple of years ago and forced a sequence of profit warnings. A £60m share sale in February 2018 helped to straighten out the Aim-quoted concern’s finances, new management came aboard in late 2019 and the pace of purchases slowed so that the company could focus on the day job.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...